Amarin Corp Plc (AMRN)

[Sam81]

Suntrust New Update (09/11/2015):

https://drive.google.com/file/d/0B1gB2YESBJV7VGFmZlVwOUxsTW8/view


What's Incremental To Our View
New data from the CHERRY study is supportive of AMRN’s REDUCE-IT CV outcomes study hypothesis. The study showed a stat. significant reduction in plaque, lipid & fibrous volumes in patients using Vascepa + statin vs. statin alone. Under its Free Speech win in the courts, AMRN can promote these findings through its sales force. We expect sales force promotion of JELIS (-53% reduction in CV risk) & CHERRY to fuel Rx growth enabling AMRN to be cash flow (+) in ’16. Risk/reward looks attractive; with performance driven by Rx trends & a free call option on its REDUCE-IT trial. Reiterate Buy/$6PT